Scientific Programme Information

The Symposium programme offers three full days of presentations by the best of the best in Targeted Alpha Therapy. As we gear up for TAT 12, we are pleased to share the detailed Symposium programme as well as the posters.


DR Chandra Sekhar Bal MD, DNB, D.Sc. FAMS, FNASc, FASc

Professor & Head of Nuclear Medicine Department at AIIMS, New Delhi

Awarded Brg Mazumdar Oration by SNM, India

RD Lele Oration by ANMPI, Oration Award by Indian Society of Thyroid Surgeons and Oration Award by IGCD Academy at Metabolic Conclave-Dubai

AIIMS Excellence in Clinical Research 2015, 2017 and 2019, 2020 & 2021

EANM-Springer Award 2019 as Best Published Paper

2021 & 2022 Dr. Henry N Wagner Jr. Best Research Paper of the Year by SNMMI, USA

Special Interest in Therapy: Radioiodine Treatment of Hyperthyroidism & Thyroid Cancer, PRRT, PSMA Therapy in mCRPC, Neuroimaging, etc

Experience of Treating more than 12,000 Thyroid cancer patients at institute

Written 510 original research articles, edited 3 Books and contributed 40 book chapters

Ex-President -ANMPI & Ex-President- Indian Thyroid Society, and Ex-President- FAIIMS, New Delhi

Professor Dr. Richard P. Baum (Wiesbaden) – Chairman of the Scientific Board

Richard P. Baum is Director of the Advanced Theranostics Center for Radiomolecular Precision Oncology, Curanosticum at Deutsche Klinik für Diagnostik (DKD HELIOS Klinik), Wiesbaden, Germany. Professor Baum is also the President of the ICPO Academy and previous President of WARMTH (World Association of Radiopharmaceutical and Molecular Therapy) and of the International Research Group on Immuno-Scintigraphy and Therapy (IRIST). He is the co-founder – together with Prof. Frank Rösch – of the Theranostics World Congress (TWC) n 2011.

Dr. Cathy Cutler B

Brookhaven National Laboratory, New York

Cathy S. Cutler, Ph.D. is Director of the Medical Isotope Research Production and Development group (MIRP) at Brookhaven National
Laboratory. Dr. Cutler earned the Bachelor of Sciences in Biochemistry in 1988 and a Doctorate in Inorganic Chemistry in 1993 from the University
of Cincinnati. Dr. Cutler then joined the Radiation Sciences group at Washington University School of Medicine and developed and characterized a Ga‐68 brain agent that crosses the intact blood brain barrier; designed studies to determine how in vivo metabolism affects compounds distribution, clearance and target selectivity; and collaborated to radiolabel and evaluate peptides containing unique amino acids with modified side chains to bind metals such as technetium, rhenium and rhodium. It was this collaboration that drew Dr. Cutler to the University of Missouri Research Reactor Centers Radiopharmaceuticals Group in 1998, where she worked until June 2015. Additionally, she directs the Target Processing Labs (TPL).
Dr. Cutler’s research focuses on developing production and separation methods for high specific activity radioisotopes, creating a suite of diagnostic and therapeutic agents tailored for individual needs, which has been funded by the DOE, NIH, NSF and public foundations.
She brings more than 20 years of experience in the development and evaluation of radiopharmaceuticals, utilizing bioinorganic and radioanalytical chemistry to develop and evaluate radiopharmaceuticals for both diagnosis and therapy.

Elba Etchebehere 

Professor of Nuclear Medicine at the University of Campinas and the administrative director of the largest nuclear medicine private practice in Brazil (the MND Group). She has approximately 120 publications of complete scientific articles, 164 published abstracts (61% international), and 290 congress presentations. She has published one book and 15 book chapters, has won 23 scientific prizes (6 international), has delivered more than 200 speeches at conferences, has organised 25 scientific events (3 international), and has participated on the editorial board of 16 journals (80% international). 

Dr. Benedikt Feuerecker 

Dr. Benedikt Feuerecker, MBA is a nuclear medicine physician, currently in training as radiologist in the department of radiology, LMU Klinikum, Munich. He received his residency training as nuclear medicine physician in the department of nuclear medicine, Klinikum rechts der Isar, Technical University of Munich. His research activity focusses on theranostics of urogenital tumors, including 177Lu-PSMA and 225Ac-PSMA-617 in patients with metastatic castration resistant prostate cancer. He recently received his venia legendi at the Technical University of Munich.

Professor Glenda Gray 

Professor Glenda Gray (MBBCh, FC Paeds, DSc (hc), PhD (hc), LLd (hc), OMS) is the first female President and CEO of the South African Medical Research Council (SAMRC). She is also Research Professor in Paediatrics at the University of the Witwatersrand, and Member (Professor) in the Vaccine and Infectious Disease Division at the Fred Hutch Cancer Research Center in Seattle.

In her first five-year tenure at the helm of the SAMRC the organisation experienced five consecutive clean audits; transformed grant funding initiatives that significantly improved funding for young scientists, black African scientists, and women; and established key collaborations and partnerships that will significantly progress scientific research.

Professor Gray studied medicine and paediatrics at Wits University where she remains a Full Professor: Research in the School of Clinical Medicine. A National Research Foundation A1-rated scientist, Professor Gray is world-renowned for her research in HIV vaccines and interventions to prevent mother-to-child transmission of HIV. She co-founded and led, with James McIntyre, the globally eminent Perinatal HIV Research Unit at Chris Hani Baragwanath Hospital in Soweto. For this work, she and McIntyre received the Nelson Mandela Health and Human Rights Award in 2002.

She is co-Principal Investigator of the National Institutes of Health-funded HIV Vaccine Trials Network (HVTN) and directs the programme in Africa. Amongst many others, Professor Gray’s accolades include the Hero of Medicine Award from the International Association of Physicians in AIDS Care, and the Outstanding Africa Scientist Award from the European and Developing Countries Clinical Trials Partnership.

Forbes named Professor Gray one of Africa’s 50 Most Powerful Women in 2020 and was named by Time Magazine in 2017 one of the world’s 100 Most Influential People. In 2013 she was awarded South Africa’s highest honour, the Order of Mapungubwe. For her research in HIV, she has been awarded the Nelson Mandela Health and Human Rights Award (2002), the IAPAC Hero in Medicine Award (2003), the Ngaly-Mann lectureship at CROI (2010), two Honorary Doctorates in Science from Simon Fraser University (2013) and Stellenbosch University (2017), and an honorary Doctorate in Law in 2019 (Rhodes University).

Her qualifications include MBBCh (Wits), FCPaeds (SA), DSc (honoris causa Simon Fraser University), DSc (honoris causa Stellenbosch University), and LLD (honoris causa Rhodes University).

Urs B Hagemann, PHD

Urs has 10 years of experience in the field of Targeted Radiotherapy, contributing to the establishment of the Targeted Thorium-227 Conjugates (TTCs) and the newer Targeted Actininum-225 Conjugate platform. Urs joined Bayer in Berlin in 2017, advancing TTC projects from research into clinical development. Urs started his career in a biotech company (Affitech, Oslo/Norway 2008 – 2012) before joining Algeta (Oslo/Norway), which was subsequently acquired by Bayer. Since April 2022, Urs officially leads the targeted radiopharmaceutical research department, based in Berlin/Germany.

Urs has a background in molecular biology and holds a PhD degree within protein engineering from the University of Freiburg/Germany.

Clemens Kratochwil, MD

Dr. Kratochwil studied medicine at the University of Ulm in Germany. After graduating from medical school, his residency led him through the Departments of Nuclear Medicine of the University Hospital Ulm, Technical University Munich and Heidelberg University Hospital. He received his Doctors Degree (“18F-FLT for monitoring treatment response”) in 2008. Since 2010 he worked as a consultant and since 2013 as the supervising physician of the radionuclide ward of Heidelberg University Hospital.

His clinical and preclinical scientific interest is focused on targeted alpha-emitter therapy. Work related to 213Bi-Dotatoc was decorated with the SNM Nuclear Oncology Council Young Investigator Award and the RSNA Trainee Research Prize in 2011. Work related to 225Ac-PSMA617 with the EANM Marie Curie Award and the Therapy Award of the German society of Nuclear Medicine. Using ²⁰³Pb surrogate imaging, he explored PSMA-ligands with favorable characteristics for ²¹²Pb labeling. As a nuclear medicine professional and researcher, he already (co)authored approx. 180 peer-reviewed articles.

Katharina Lückerath

Prof. Dr. Lückerath is a biomedical scientist with a focus on experimental and translational theranostics. A priority of her research is on delivering new insights into tumour biology and its relationship and relevance to functional imaging and biomarker-driven treatments in nuclear medicine. Prof. Dr. Lückerath obtained her PhD at the Institute for Tumor Biology and Experimental Therapy (Georg-Speyer-Haus, Germany). She served as head of the research group Experimental Oncology in Nuclear Medicine at the University of Würzurg (Germany), and of the pre-clinical Nuclear Medicine team at the University of California Los Angeles (USA; with Johannes Czernin), before transferring to University Hospital Essen in March 2021 as professor of Preclinical Theranostics. 

Professor Agnieszka Majkowska-Pilip

Agnieszka Majkowska-Pilip is Associate Professor in the Institute of Nuclear Chemistry and Technology (INCT) in Warsaw. Since 2021 she also works as radiopharmacist in the National Medical Institute of Central Clinical Hospital of the Ministry of Interior and Administration in Warsaw.

She obtained her PhD in 2010 (“44/47Sc complexes with multidentate ligands as radiopharmaceutical precursors”) and in years 2010-2013 she worked as a postdoctoral researcher in European Commission, Join Research Centre in Karlsruhe. Her studies were focused on the  synthesis and in vitro evaluation of 225Ac-DOTA-SubstanceP for targeted alpha therapy of glioblastoma multiforme. She obtained the title of doctor habilitated in 2022 with her thesis entitled“SubstanceP peptide and trastuzumab monoclonal antibody radiobioconjugates labeled with corpuscular emitters for targeted radionuclide therapy”.

Prof. Majkowska-Pilip has a strong experience in the field of radiopharmacy. Her research is mostly focused on the synthesis and biological studies (in vitro/in vivo) of novel radiopharmaceuticals for targeted therapies of various cancers like neuroendocrine tumors, glioblastoma multiforme, cervical and breast carcinomas. In addition, she specializes in the development of nanoparticles as carriers for

chemotherapeutics and radionuclides – multimodal nanoparticles.

She has published almost 40 scientific papers in peer-reviewed journals and holds two patents.

Rodolfo Núñez

Rodolfo Núñez, M.D. is a Board Certified Nuclear Medicine physician with more than 25 years of professional experience. Although he is originally from Madrid (Spain), where he studied Medicine, his postgraduate training has been in the USA. First, in Internal Medicine and subsequently in Nuclear Medicine, including residency and fellowship training at Memorial Sloan-Kettering Cancer Center in New York. He has worked at different facilities and institutions including as UN officer at the International Atomic Energy Agency (IAEA), as faculty in different University Hospitals, including The University of Texas MD Anderson Cancer Center, and in private practice at Excel Diagnostics and Nuclear Oncology Center in Houston, TX. Recently, he was appointed Chief of Nuclear Medicine at Tufts University Medical Center in Boston. His area of expertise is Nuclear Oncology in general, including PET/CT imaging and Theranostics.

Dr. Jean-Pierre Pouget

Dr Jean-Pierre Pouget obtained his PhD thesis in Radiobiology in 2000 from the Curie Institute in Paris and carried-out a post-doctoral fellowship in the Nuclear Medicine Research Laboratory at Barts and the London School of Medicine and Dentistry.  He then moved to Paris to the French Radiation Protection and Nuclear Safety Agency (IRSN) for 4 years where he worked on radiation casualties.

After moving to Montpellier, he joined the French National Institute for Health and Medical research (INSERM) where he is now Research Director and leader of the “Radiobiology for Targeted and Personalized Radiotherapy” team at the Cancer Research Institute of Montpellier (INSERM, France).

His work is mainly focused on the radiobiology of radiopharmaceuticals used for cancer imaging and therapy (“targeted radionuclide therapy”, TRT). More specifically, he investigates the role of the so called targeted (radiative) and non-targeted (bystander and systemic/immune) effects of TRT. Those effects involve intercellular communications mediated by small extracellular vesicles and immune system activation through cGAS-STING pathways. The final aim of his multidisciplinary team is to optimize cancer TRT by a better understanding of radiobiological aspects.

He has published more than 90 papers and book chapters dealing with radiobiology and radionuclide therapy and several patents. Besides research activity, Dr Pouget is involved in teaching at the University of Montpellier, INSTN Saclay, University of Grenoble and University of Marseille. He is also member of Frontiers in nuclear medicine and Current radiopharmaceuticals editorial boards. He is member of the EANM TMI&T committee, leader of the EANM radiobiology group and a founding member of the European working group in radiobiology of MRT ( and of the French Society of Radiation Biology (SFBR).

Hendrik Gabriel Rathke

Hendrik Gabriel Rathke (PD Dr. med.) is Senior Registrar (since 2021) and Lecturer (since 2022) in Nuclear Medicine, University Hospital, Bern, Inselspital, Switzerland (Prof. A. Rominger). He is NM Specialist in Nuclear Medicine, University Hospital, Heidelberg, Germany (Prof. U. Haberkorn) since 2020. His professional qualifications include Charité University Hospital Berlin, Germany, license to practice medicine, 2015; Heidelberg University Hospital, Germany, Board Certificate for Nuclear Medicine in Germany, 2020; Mebeko Board Certificate for Nuclear Medicine in Switzerland, 2021; and Heidelberg University Hospital, Germany, Venia legendi Nuclear Medicine, 2022.  

His experience and current and previous positions include Charité University Hospital Berlin, Germany, Internship in Cardiology, 2013; Charité University Hospital Berlin, Germany, Internship in Surgery, 2013; Charité University Hospital Berlin, Germany, Internship in Radiology, 2013-2014; Heidelberg University Hospital, Germany, Fellowship in Nuclear Medicine, 2015-2020; Heidelberg University Hospital, Germany, Nuclear Medicine Specialist, 2020; and Inselspital Bern, Switzerland, Senior consultant, 2021. 

Prof. Oliver Sartor

Prof Oliver Sartor is an internationally recognized expert in prostate cancer. His medical practice and research have focused on prostate cancer since 1990, when he finished a fellowship at the National Cancer Institute (NCI). He has published over 300 articles and book chapters and led multiple national and international clinical trials as principal investigator or co-principal investigator. In particular, he has helped to lead pivotal trials leading to FDA approval for samarium-153 EDTMP, radium-223, and cabazitaxel. He has lectured widely and, at last count, has given invited lectures in 28 countries. Now recently for 177Lu-PSMA in Prostate cancer – Lead author of the Vision trial in NEJM.

He is currently the Assistant Dean for Oncology at Tulane University School of Medicine, Medical Director of the Tulane Cancer Center, and the Laborde Professor for Cancer Research, with appointments in the Medicine and Urology Departments.

He has served as the past Chairman of the Department of Defense Prostate Cancer Integration Panel, is currently Editor-in-Chief of the peer-reviewed journal Clinical Genitourinary Cancer and is the Medical Oncology Chair of the GU committee of NRG. He is also currently a member of the NCI Board of Scientific Counselors (Clinical Sciences and Epidemiology).

Mike Sathekge

Mike Sathekge is a Professor and Head of Nuclear Medicine department at University of Pretoria and Steve Biko Academic Hospital. He heads the South African Nuclear Medicine Research Infrastructure. Prof Sathekge has published over 230 peer-reviewed articles, excluding abstracts and book chapters. He is one of the global leaders concerning treatment of prostate cancer using targeted alpha therapy. He also led and introduced several targeted molecular imaging and therapeutic probes in infection and oncology in Africa. Mike is the Editor-in-Chief of Seminars in Nuclear Medicine and an Associate Editor of the European Journal of Nuclear Medicine and Molecular Imaging and the Journal of Nuclear Medicine (top journals in nuclear medicine).  Prof Sathekge is the President of the World Association of Radiopharmaceuticals and Molecular Therapy and the chair of the ASSAf panel on research, development and innovation of peaceful uses of nuclear technologies in South Africa. Mike holds numerous scientific honours and awards.

George Sgouros

George Sgouros is Professor and Director of the Radiological Physics Division in the Department of Radiology at Johns Hopkins University, School of Medicine. The focus of his research is on modelling and dosimetry of internally administered radionuclides with a particular emphasis on patient-specific dosimetry, alpha-particle dosimetry, and mathematical modelling of radionuclide therapy. 

Dr Sgouros is author on more than 200 peer-reviewed articles, as well as several book chapters and review articles. He is the recipient of the SNMMI Saul Hertz Award for outstanding achievements and contributions in radionuclide therapy. He is a member of the Medical Internal Radionuclide Dose (MIRD) Committee of the Society of Nuclear Medicine and Molecular Imaging (SNMMI), which he chaired from 2008 to 2019. He has served as chairman of the Dosimetry and Radiobiology Panel at a Department of Energy Workshop on alpha-emitters in medical therapy and, in the early 90s, provided the physics/dosimetry support for the first FDA-approved human trial of targeted Alpha-emitter therapy. 

He is also a member of the International Commission on Radiation Units and Measurements (ICRU) Report Committee on “Bioeffect Modeling and Equieffective Dose Concepts in Radiation Therapy” and chair of Report Committee 31 on “Treatment Planning for Radiopharmaceutical Therapy”. Dr Sgouros served on the Scientific Committee of the IAEA/WHO Network of Secondary Standards Dosimetry Laboratories (2014-2018) and is a member of the National Council on Radiological Protection and Measurements (NCRP). Dr Sgouros is a former chair (2015-2017) of the NIH study section on Radiation Therapeutics and Biology (RTB). He was also a member of the Ad Hoc Working Group on Radiation Oncology, NIH, NCI, Clinical Trials and Translational Research Advisory Committee (2019-2021). Dr Sgouros is also founder and principal of Rapid, a start-up that provides dosimetry and imaging services and products in support of radiopharmaceutical therapy. 

Dr. Ken Song

Ken is President and CEO at RayzeBio. Ken’s experience spans clinical medicine, basic science research, product development and global commercialization, venture capital, and entrepreneurship. Ken is also the co-founder and Chairman of the Board at Ablaze Pharmaceuticals, which is focused on radiopharmaceuticals development for the Greater China market. Prior to RayzeBio, he was President and CEO of Metacrine, Inc. where he led the organization from research to mid-stage clinical development and also positioned the company for an IPO. From 2010 to 2016, Ken was the co-founder and CEO of Ariosa Diagnostics (acquired by Roche) where he led the organization from early research to global commercialization of the Harmony Prenatal Test in over 100 countries. Ken also served as Executive Chairman of Omniome (acquired by Pacific Biosciences), a sequencing technology company, helping it mature from a research to product development company.

Prior to being an operator and entrepreneur, Ken worked as a venture capitalist at Venrock as well as consultant at McKinsey & Company. Ken trained in internal medicine at the University of California, San Francisco (UCSF) and specialized in gastroenterology and hepatology at the University of Washington along with a scientific research fellowship at the Fred Hutchinson Cancer Center. He earned his B.S. from Massachusetts Institute of Technology and M.D. from UCSF.

Dr. Nicholas van der Meulen

Dr. Nicholas van der Meulen hails from Cape Town, South Africa, and currently resides in North West Switzerland. He obtained his PhD in Chemistry from Stellenbosch University in 2008, with his thesis work concentrating on the production of various radionuclides (Ga-67, Ge-68, Sr-82, Y-88, etc.), predominantly for medical purposes. He worked as a research chemist for the Radionuclide Production Group at iThemba Laboratory for Accelerator Based Sciences (iThemba LABS) for 17 years, before taking up the position of Group Leader: Radionuclide Development at Paul Scherrer Institute, Switzerland, in 2013. He is actively involved in the development of exotic radionuclides towards preclinical/clinical application, as well as the supervision of students in this field. His current focus is on the “matched pair” principle in radiotheragnostics, particularly concentrating on terbium and scandium radioisotopes. The development thereof has led to first-in-human application of terbium-152, terbium-161 and cyclotron-produced scandium-44. He has been instrumental in the development of terbium-161, where it is currently being prepared for a clinical trial as 161Tb-DOTA-LM3. He represents Switzerland on various EU and IAEA platforms based on his expertise and experience in radionuclide development.

Alyssa Vito

Alyssa Vito is a Senior Scientist, Translational Sciences at POINT Biopharma. Alyssa is responsible for advancing novel radioligand therapeutics programs from early discovery to IND-enabling studies as well as overseeing strategic translational science to advance clinical programs to Phase II and beyond. Alyssa is a multidisciplinary scientist with experience in organic chemistry, radiochemistry, cancer biology & tumor immunology. She has a Ph.D. in Biochemistry and Biomedical Sciences and holds a master’s degree in Chemical Biology from McMaster University.

Dr. Richard Zimmermann

Dr. Richard Zimmermann is an independent consultant specialized in the field of R&D in Nuclear Medicine as well as in economics and the industrial aspects of radiopharmaceuticals. He gained his experience after having first spent 15 years in the conventional pharmaceutical industry in R&D departments with Beecham and Solvay Pharmaceuticals. In 1998, he joined the radiopharmaceutical industry, successively as head of R&D, head of PET development, VP Business Development within CISbio, Schering and IBA Molecular. During this period, he did also lead the AIPES PET working group for three years, formed the Belgium entity and in 2011, created Oncidium, a foundation supporting the development of radiotherapeutics. In 2012, he created his own consulting company, Chrysalium Consulting, specialized in the support and industrialization of radiopharmaceuticals. He was President of the French company Medisystem (2013-2017, now LemerPax) and President of the Belgian company ANMI (2015-2018, now Telix). He was involved in the foundation of the Australian company Telix Pharmaceuticals for which he was non-executive director during the first year. He was also co-founder and General Manager of Global Morpho Pharma SAS.

So far, he did spend 25 years in the Nuclear Medicine environment and he published several review articles as well as a general audience book on that topic translated in French, English and Spanish. His main interest is now focused on the long-term evolution of nuclear medicine through the identification and evaluation of industrial, regulatory, and economic constraints with expert reports published yearly since 2014 through the partnership MEDraysintell. The 9th edition of this report (3,200+ pages) was published in September 2023.

Call for Abstracts

The Call for Abstracts closed on 15 December 2022.

The TAT 12 proceedings will be published in the International Journal of Molecular Sciences (IJMS)

Impact Factor = 6.208

Subjects that will be addressed at TAT 12

Pre-clinical Studies and Experiences
Clinical Experiences and Applications of Alpha Emitting Isotopes
Nuclide Production/ Supply
Targeting and Delivery Systems (e.g. new chelation, nanocarriers, encapsulation approaches, etc.)
Quality and Regulatory Aspects (e.g. Handling of alpha emitters in clinics, dealing with waste, FDA approvals etc.)
Related Topics

Programme at a Glance

Programme Overview

Clinical Day

With Targeted Alpha Therapy treatments beginning to hit the market, the clinical perspective has become an essential part of the TAT conversation. The TAT Clinical Day, including an all-day clinical track featuring leading practitioners in the field. Learn first-hand about the challenges and opportunities presented by Targeted Alpha Therapies from the world’s top clinical experts.


At the tip of Africa, and about 40 km, from Cape Town lies iThemba LABS (Laboratories for Accelerator Based Sciences). It is the premier particle accelerator facility on the African continent, and the only facility of its kind in the southern hemisphere. The workhorse of iThemba LABS is the k=200 Separated Sector Cyclotron (SSC) to provide accelerated particle beams. The SSC established itself over many years as the enabler of two types of activities, namely isotope production for nuclear medicine and basic and applied research, which includes radiation biology and neutron physics and metrology. We are excited about the fact that 2023 is the year that we bring the South African Isotope Facility (SAIF) online and migrate the production of I123, Na22, Ge68 and Sr82 to a dedicated 70-MeV cyclotron. This will not only free up the SSC for fundamental and applied research, but it will also accelerate our R&D efforts in nuclear medicine such as Theranostics and targeted alpha therapy (TAT).

Scheduled Site Visits

Mon, 27 February at 13h00 and Friday, 3 March at 10h30

See registration and above programme for further information